Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Berthaud

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
European Journal of Cancer & Clinical Oncology|October 1, 1989
Phase II study of pirarubicin in advanced non-small cell lung cancerP Berthaud, T Le Chevalier, J Berille, et al.
European Journal of Cancer & Clinical Oncology|September 1, 1989
Phase II study of pirarubicin in advanced non-small cell lung cancerP Berthaud, T Le Chevalier, J Berille, et al.
European Journal of Cancer & Clinical Oncology|November 1, 1989
Phase II multicentre study of the nitrosourea fotemustine in inoperable squamous cell lung carcinomaT Le Chevalier, C Zabbe, S Gouva, et al.
Bulletin Du Cancer|January 1, 1989
[Results of a phase II study of the combination of cis-platinum and 5-FU in epidermoid or undifferentiated large cell bronchial cancer]A Rivière, D Abouz, P Ayela, et al.
Leukemia|June 1, 2002
Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571R Tabrizi, F X Mahon, P Cony Makhoul, et al.
Presse Medicale (Paris, France : 1983)|February 16, 1991
[Phase I trial of a recombinant human interleukin 2. Results in patients with disseminated solid tumors]T Tursz, T Dorval, P Berthaud, et al.
Annals of Hematology|May 6, 2004
Priming with GM-CSF for acute myelogenous leukemia (AML): GOELAM dataF Witz, J L Harousseau, F Guilhot, et al.
Leukemia & Lymphoma|July 1, 1996
Idarubicin and high dose cytarabine: a new salvage treatment for refractory or relapsing non-Hodgkin's lymphomaP Dufour, R Mors, P Berthaud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III studyJ L Pujol, J Y Douillard, A Rivière, et al.
Leukemia|March 1, 1996
A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75J Reiffers, F Huguet, A M Stoppa, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
European Journal of Cancer & Clinical Oncology|October 1, 1989
Phase II study of pirarubicin in advanced non-small cell lung cancerP Berthaud, T Le Chevalier, J Berille, et al.
European Journal of Cancer & Clinical Oncology|September 1, 1989
Phase II study of pirarubicin in advanced non-small cell lung cancerP Berthaud, T Le Chevalier, J Berille, et al.
European Journal of Cancer & Clinical Oncology|November 1, 1989
Phase II multicentre study of the nitrosourea fotemustine in inoperable squamous cell lung carcinomaT Le Chevalier, C Zabbe, S Gouva, et al.
Bulletin Du Cancer|January 1, 1989
[Results of a phase II study of the combination of cis-platinum and 5-FU in epidermoid or undifferentiated large cell bronchial cancer]A Rivière, D Abouz, P Ayela, et al.
Leukemia|June 1, 2002
Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571R Tabrizi, F X Mahon, P Cony Makhoul, et al.
Presse Medicale (Paris, France : 1983)|February 16, 1991
[Phase I trial of a recombinant human interleukin 2. Results in patients with disseminated solid tumors]T Tursz, T Dorval, P Berthaud, et al.
Annals of Hematology|May 6, 2004
Priming with GM-CSF for acute myelogenous leukemia (AML): GOELAM dataF Witz, J L Harousseau, F Guilhot, et al.
Leukemia & Lymphoma|July 1, 1996
Idarubicin and high dose cytarabine: a new salvage treatment for refractory or relapsing non-Hodgkin's lymphomaP Dufour, R Mors, P Berthaud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III studyJ L Pujol, J Y Douillard, A Rivière, et al.
Leukemia|March 1, 1996
A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75J Reiffers, F Huguet, A M Stoppa, et al.
Pageof 3